Therapy and outcome at initial presentation and before and after pembrolizumab treatment of 7 patients with NK/T-cell lymphoma treated with pembrolizumab
| Case . | Primary treatment . | Before pembolizumab . | Pembrolizumab treatment . | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CTx (cycles) . | RT . | Outcome . | Other Rx . | DOR, months . | CTx (cycles) . | Outcome . | DOR, mo . | PDL1 . | Dose, mg . | Cycles . | Outcome (cycles) . | Survival, mo . | |
| 1 | SIMPLE (6) | Nil | CR | Nil | 17 | Nil | NA | NA | Strong | 100 | 6 | PET/CT, Deauville score, 3 (4) | 4+ |
| EBV DNA: negative (1) | |||||||||||||
| 2 | SMILE (5) | Nil | CR | Allo-HSCT | 83 | Nil | NA | NA | Strong | 120 | 7 | PR, DOD | 6 |
| 3 | m-BACOD (4) | Yes | CR | Nil | 63 | SIMPLE (6) | CR | 20 | Strong | 100 | 12 | Pseudoprogression (3, 6, and 9); CR (12) | 10+ |
| SMILE (3) | PD | NA | EBV DNA: negative (1) | ||||||||||
| 4 | GELOX (3) | Nil | CR | Nil | 4 | SMILE (5) | PD | NA | Strong | 200 | 13 | Morphologic CR (6) | 8+ |
| RV (2) | PD | PET/CT CR (6) | |||||||||||
| BB (2) | PD | EBV DNA: negative (3) | |||||||||||
| DaraRev (1) | PD | EBV DNA then became positive | |||||||||||
| 5 | SMILE (6) | Yes | CR | Nil | 7 | GEMOX (1) | PD | NA | 20% | 100 | 2 | EBV DNA: negative | 2 |
| RT | PD | Died as a result of gastric ulcer bleeding | |||||||||||
| 6 | SMILE (1) | Yes | NA | Nil | 2 | GELOX (6) | PR | 6 | ND | 100 | 12 | CR (6) | 9+ |
| 7 | SMILE (6) | Nil | CR | Allo-HSCT | 10 | Nil | NA | NA | ND | 100 | 4 | CR (3) | 3+ |
| Case . | Primary treatment . | Before pembolizumab . | Pembrolizumab treatment . | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CTx (cycles) . | RT . | Outcome . | Other Rx . | DOR, months . | CTx (cycles) . | Outcome . | DOR, mo . | PDL1 . | Dose, mg . | Cycles . | Outcome (cycles) . | Survival, mo . | |
| 1 | SIMPLE (6) | Nil | CR | Nil | 17 | Nil | NA | NA | Strong | 100 | 6 | PET/CT, Deauville score, 3 (4) | 4+ |
| EBV DNA: negative (1) | |||||||||||||
| 2 | SMILE (5) | Nil | CR | Allo-HSCT | 83 | Nil | NA | NA | Strong | 120 | 7 | PR, DOD | 6 |
| 3 | m-BACOD (4) | Yes | CR | Nil | 63 | SIMPLE (6) | CR | 20 | Strong | 100 | 12 | Pseudoprogression (3, 6, and 9); CR (12) | 10+ |
| SMILE (3) | PD | NA | EBV DNA: negative (1) | ||||||||||
| 4 | GELOX (3) | Nil | CR | Nil | 4 | SMILE (5) | PD | NA | Strong | 200 | 13 | Morphologic CR (6) | 8+ |
| RV (2) | PD | PET/CT CR (6) | |||||||||||
| BB (2) | PD | EBV DNA: negative (3) | |||||||||||
| DaraRev (1) | PD | EBV DNA then became positive | |||||||||||
| 5 | SMILE (6) | Yes | CR | Nil | 7 | GEMOX (1) | PD | NA | 20% | 100 | 2 | EBV DNA: negative | 2 |
| RT | PD | Died as a result of gastric ulcer bleeding | |||||||||||
| 6 | SMILE (1) | Yes | NA | Nil | 2 | GELOX (6) | PR | 6 | ND | 100 | 12 | CR (6) | 9+ |
| 7 | SMILE (6) | Nil | CR | Allo-HSCT | 10 | Nil | NA | NA | ND | 100 | 4 | CR (3) | 3+ |
Allo-HSCT, allogeneic hematopoietic stem-cell transplantation; BB, brentuximab vedotin and bendamustine; CR, complete response; CTx, chemotherapy; DaraRev, daratumomab and lenalidomide; DOD, died of disease; GELOX, gemcitabine, l-asparaginase, and oxaliplatin; m-BACOD, methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone; NA, not applicable; ND, not done; PR, partial response; RT, radiotherapy; RV, romidepsin and bortezomib; SIMPLE, dexamethasone, ifosfamide, gemcitabine, cisplatin, L-asparaginse, and etoposide; SMILE, dexamethasone, methotrexate, ifosfamide, l-asparaginase, and etoposide.